Cargando…
Impact of Type II LRRK2 inhibitors on signaling and mitophagy
Much effort has been devoted to the development of selective inhibitors of the LRRK2 as a potential treatment for LRRK2 driven Parkinson's disease. In this study, we first compare the properties of Type I (GSK3357679A and MLi-2) and Type II (GZD-824, Rebastinib and Ponatinib) kinase inhibitors...
Autores principales: | Tasegian, Anna, Singh, Francois, Ganley, Ian G., Reith, Alastair D., Alessi, Dario R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589421/ https://www.ncbi.nlm.nih.gov/pubmed/34515301 http://dx.doi.org/10.1042/BCJ20210375 |
Ejemplares similares
-
Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms
por: Malik, Asad U., et al.
Publicado: (2021) -
Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity
por: Kalogeropulou, Alexia F., et al.
Publicado: (2020) -
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding
por: Kalogeropulou, Alexia F., et al.
Publicado: (2022) -
Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites
por: Nirujogi, Raja S., et al.
Publicado: (2021) -
Pharmacological rescue of impaired mitophagy in Parkinson’s disease-related LRRK2 G2019S knock-in mice
por: Singh, Francois, et al.
Publicado: (2021)